Literature DB >> 24589271

Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Zahra Pakbaz1, Ted Wun2.   

Abstract

Recent studies suggest that sickle cell disease (SCD) is a hypercoagulable state contributing to vaso-occlusive events in the microcirculation, resulting in acute and chronic sickle cell-related organ damage. In this article, we review the existing evidence for contribution of hemostatic system perturbation to SCD pathophysiology. We also review the data showing increased risk of thromboembolic events, particularly newer information on the incidence of venous thromboembolism. Finally, the potential role of platelet inhibitors and anticoagulants in SCD is briefly reviewed. Published by Elsevier Inc.

Entities:  

Keywords:  Anti-platelets; Anticoagulants; Hypercoagulable; Sickle cell; Thromboembolism

Mesh:

Substances:

Year:  2014        PMID: 24589271      PMCID: PMC3984936          DOI: 10.1016/j.hoc.2013.11.011

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  149 in total

1.  Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study.

Authors:  J B Schnog; A P Kater; M R Mac Gillavry; A J Duits; L R Lard; F P van Der Dijs; D P Brandjes; H ten Cate; L W van Eps; R A Rojer
Journal:  Am J Hematol       Date:  2001-11       Impact factor: 10.047

2.  Thrombophilia in sickle cell disease: the red cell connection.

Authors:  B N Setty; A K Rao; M J Stuart
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

3.  Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state.

Authors:  A K Bayazit; Y Kilinç
Journal:  Pediatr Int       Date:  2001-12       Impact factor: 1.524

4.  Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms.

Authors:  K Joop; R J Berckmans; R Nieuwland; J Berkhout; F P Romijn; C E Hack; A Sturk
Journal:  Thromb Haemost       Date:  2001-05       Impact factor: 5.249

5.  Pulmonary thrombotic arteriopathy in patients with sickle cell disease.

Authors:  M O Adedeji; J Cespedes; K Allen; C Subramony; M D Hughson
Journal:  Arch Pathol Lab Med       Date:  2001-11       Impact factor: 5.534

6.  Modulation of nitric oxide bioavailability by erythrocytes.

Authors:  K T Huang; T H Han; D R Hyduke; M W Vaughn; H Van Herle; T W Hein; C Zhang; L Kuo; J C Liao
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

7.  Pulmonary embolism in sickle cell disease: a case-control study.

Authors:  E M Novelli; C Huynh; M T Gladwin; C G Moore; M V Ragni
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

8.  Thrombogenesis in sickle cell disease.

Authors:  A Tomer; L A Harker; S Kasey; J R Eckman
Journal:  J Lab Clin Med       Date:  2001-06

9.  Causes of death in sickle cell disease: an autopsy study.

Authors:  Elizabeth A Manci; Donald E Culberson; Yih-Ming Yang; Todd M Gardner; Randall Powell; Johnson Haynes; Arvind K Shah; Vipul N Mankad
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

10.  Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes.

Authors:  Arun S Shet; Omer Aras; Kalpna Gupta; Mathew J Hass; Douglas J Rausch; Nabil Saba; Louann Koopmeiners; Nigel S Key; Robert P Hebbel
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

View more
  17 in total

1.  Sickle cell disease is associated with iron mediated hypercoagulability.

Authors:  Nirmish Shah; Ian J Welsby; Martha A Fielder; Wayne K Jacobsen; Vance G Nielsen
Journal:  J Thromb Thrombolysis       Date:  2015-08       Impact factor: 2.300

Review 2.  Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.

Authors:  Ram Kalpatthi; Enrico M Novelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

4.  Increased Level of Factor VIII and Physiological Inhibitors of Coagulation in Patients with Sickle Cell Disease.

Authors:  Mohamed Chekkal; Mohamed Chakib Arslane Rahal; Khedidja Moulasserdoun; Fatima Seghier
Journal:  Indian J Hematol Blood Transfus       Date:  2016-06-25       Impact factor: 0.900

5.  Protein Z and Endothelin-1 genetic polymorphisms in pediatric Egyptian sickle cell disease patients.

Authors:  Mervat M Khorshied; Nohair S Mohamed; Rania S Hamza; Rasha M Ali; Mona K El-Ghamrawy
Journal:  J Clin Lab Anal       Date:  2017-05-26       Impact factor: 2.352

6.  Computational imaging analysis of fibrin matrices with the inclusion of erythrocytes from homozygous SS blood reveals agglomerated and amorphous structures.

Authors:  Rodney D Averett; David G Norton; Natalie K Fan; Manu O Platt
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

Review 7.  How I diagnose and treat venous thromboembolism in sickle cell disease.

Authors:  Arun S Shet; Ted Wun
Journal:  Blood       Date:  2018-05-15       Impact factor: 22.113

Review 8.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

9.  Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.

Authors:  Anwar Al-Awadhi; Adekunle Adekile; Rajaa Marouf
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

10.  Lectin-like oxidized low-density lipoprotein receptor (LOX-1) in sickle cell disease vasculopathy.

Authors:  Mingyi Chen; Hong Qiu; Xin Lin; David Nam; Lucy Ogbu-Nwobodo; Hannah Archibald; Amelia Joslin; Ted Wun; Tatsuya Sawamura; Ralph Green
Journal:  Blood Cells Mol Dis       Date:  2016-06-25       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.